---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063953"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T15:49:47.133853+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q1 net loss $53.1M; lowers FY2025 net sales guidance to $808-816M

## Summary
- Q1 pro forma net sales $189.2M, up 4.3% constant currency YoY; GAAP net loss $53.1M ($1.35/share) vs $36.0M loss year ago.
- Non-GAAP pro forma adjusted EBITDA $11.4M (6.0% margin), up 49% vs $7.7M in Q1 2024; adjusted gross margin 70.3%.
- Lowered FY2025 net sales guidance to $808-816M (pro forma) from $818-826M; reaffirms adjusted EBITDA $82-86M and positive free cash flow.
- U.S. Spine Fixation +4%, BGT +5%, Global Orthopedics constant currency +11% YoY; TrueLok Elevate TBT System received FDA clearance.
- Management cites commercial channel optimization causing temporary softness; expects growth to normalize after distributor transitions.

## SEC filing metadata
- accession: 0000950170-25-063953
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017025063953/0000950170-25-063953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017025063953/ofix-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063953
- JSON: https://secwatch.observer/filing/0000950170-25-063953.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.